Hemogenyx Pharmaceuticals Plc Share Price
Equities
SILF
GB00BYX3WZ24
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 GBX | +4.10% | +0.55% | -28.26% |
04-25 | EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout | AN |
04-25 | Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2021 | - | Sales 2022 | - | Capitalization | 12.98M 1.04B |
---|---|---|---|---|---|
Net income 2021 | -5M -400M | Net income 2022 | -3M -240M | EV / Sales 2021 | - |
Net cash position 2021 | 6.83M 547M | Net Debt 2022 | 890K 71.25M | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.85
x | P/E ratio 2022 |
-3.26
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.27% |
1 day | +4.10% | ||
1 week | +0.55% | ||
Current month | -6.25% | ||
1 month | -6.38% | ||
3 months | -38.89% | ||
6 months | -21.43% | ||
Current year | -28.26% |
Managers | Title | Age | Since |
---|---|---|---|
Alexis Sandler
FOU | Founder | - | 31/12/11 |
Founder | 59 | 31/12/11 | |
Elina Shrestha
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Redmond
BRD | Director/Board Member | 76 | 03/10/17 |
Marc Feldmann
CHM | Chairman | 79 | 08/04/18 |
Founder | 59 | 31/12/11 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.65 | +4.10% | 1,887,787 |
25/04/24 | 1.585 | -1.43% | 5,559,012 |
24/04/24 | 1.608 | -1.29% | 5,063,450 |
23/04/24 | 1.629 | +0.87% | 4,149,071 |
22/04/24 | 1.615 | -1.58% | 5,660,865 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-28.26% | 27.58M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SILF Stock